A 68-year-old woman with end-stage renal disease on hemodialysis presents with asymptomatic hyperkalemia (K⁺ 6.8 mEq/L, no ECG changes). She has poor dietary compliance and missed her last dialysis session. Which drug is the preferred first-line treatment for chronic management of recurrent hyperkalemia in this setting?

Explanation

## Chronic Management of Hyperkalemia in ESRD **Key Point:** Patiromer is a newer, preferred first-line agent for chronic hyperkalemia management in patients with ESRD because it is a selective potassium binder with minimal systemic absorption, better tolerability, and no sodium load — unlike older agents like sodium polystyrene sulfonate. ### Comparison of Chronic Hyperkalemia Agents | Agent | Mechanism | Onset | Duration | Sodium Load | Tolerability | Use | |-------|-----------|-------|----------|-------------|--------------|-----| | **Patiromer** | Selective K⁺ binder (non-absorbed) | 4–7 hrs | 24–48 hrs | None | Excellent; minimal GI side effects | **First-line chronic** | | **Sodium polystyrene sulfonate** | Cation exchange resin | 2–4 hrs | 4–6 hrs | High (~3–4 g Na⁺/dose) | Poor; constipation, GI upset, colitis risk | Second-line; avoid in ESRD | | **Insulin + dextrose** | Transcellular shift | 10–20 min | 4–6 hrs | None | Good but requires glucose monitoring | **Acute symptomatic only** | | **Sodium bicarbonate** | Transcellular shift | 30–60 min | Variable | High | Moderate; less reliable | Second-line; acidosis only | ### Why Patiromer is Preferred in ESRD 1. **Selective potassium binding:** Patiromer selectively binds K⁺ in the colon; minimal absorption of the polymer itself. 2. **No sodium load:** Critical in ESRD patients who are often volume-restricted and salt-sensitive. 3. **Sustained action:** Effective for 24–48 hours; can be dosed once or twice daily. 4. **Better tolerability:** Fewer GI side effects than sodium polystyrene sulfonate; no increased colitis risk. 5. **Efficacy in dialysis patients:** Reduces serum K⁺ by 0.5–1.0 mEq/L when used regularly. ### Patiromer Dosing - **Starting dose:** 8.4 g once daily (or 4.2 g twice daily) - **Titration:** Increase by 8.4 g every 1–2 weeks based on K⁺ levels - **Maximum:** 25.2 g daily - Take 3+ hours apart from other oral medications (binds other drugs) **High-Yield:** **Patiromer** and **sodium zirconium cyclosilicate (SZC)** are the two newer potassium binders approved for chronic hyperkalemia. Patiromer is more commonly used and preferred in ESRD because it has no sodium load and excellent safety profile. **Clinical Pearl:** In asymptomatic, non-ECG-positive hyperkalemia, chronic binders (patiromer, SZC) are preferred over acute transcellular shift agents (insulin, bicarbonate) because they remove potassium from the body rather than just shifting it temporarily. **Warning:** Sodium polystyrene sulfonate is now **discouraged** in ESRD because: - High sodium load worsens hypertension and fluid overload - Risk of colitis (especially with sorbitol co-administration) - Unreliable efficacy in dialysis patients - Patiromer is superior in every way